text stringlengths 1 5.46k |
|---|
54. Expression and Purification of Monoclonal Antibodies - Evitria Proposal No. 905283 - 9 September 2021 (executed) |
55. Commande Fournisseur de OSE Immunetherapeutics à Evitria - R2f. PO2105-1768 |
G-CLIPS |
56. Services Agreement between OSE Immunotherapeutic and G-CLIPS Biotech, effective as from February 9th, 2021 (executed) |
57. Services Agreement between OSE Immunotherapeutic and G-CLIPS Biotech, effective as from May 19th, 2022 (executed) |
GENEWIZ |
58. Genewiz Confidential Quotation - OSE Immunotherapeutic – 30 October 2019 (executed) |
59. Genewiz Confidential Quotation - OSE Immunotherapeutic - 17 April 2020 (executed) |
GUILLAUME ROBERT-SIEGWALD |
60. Consulting Agreement (Contrat de consultant) between OSE Immunotherapeutic and Mr Guillaume Robert-Siegwald, effective as from February 1st, 2020 (French language) (executed) |
61. Amendment 5 to the consulting Agreement (Avenant 5 au Contrat de consultant) between OSE Immunotherapeutic and Mr Guillaume Robert-Siegwald, as from June 8, 2023 (French language) (executed) |
62. Consulting Agreement between OSE Immunotherapeutic and Mr Guillaume Robert-Siegwald, effective as from February 1st, 2020 (translation from French) |
63. Amendment 5 to the consulting Agreement between OSE Immunotherapeutic and Mr Guillaume Robert-Siegwald, effective as from June 8, 2023 (translation from French) |
KAMONDI BIOANALYTICAL CONSULTANCY GMBH |
64. Consulting Agreement between OSE Immunotherapeutic and Kamondi Bioanalytical Consultancy GmbH, effective as from February 8th, 2019 (executed) |
65. Amendment 3 to the Consulting Agreement between OSE Immunotherapeutic and Kamondi Bioanalytical Consultancy GmbH, effective as from February 8th, 2023 (executed) |
MAbSILICO |
66. Agreement between OSE Immunotherapeutic and MAbSilico, effective as from January 30th, 2020 (executed) |
OLINK |
67. Quotation for OSE Immunotherapeutic SA - Explore 384 Neurology II Analysis Service - November 2, 2022 (executed) |
68. Quotation for OSE Immunotherapeutic SA - Explore 3072 Analysis Service - May 11, 2022 (executed) |
PROTOX CONSULTING |
69. Consulting Agreement (Contrat de consultant) between OSE Immunotherapeutics and Protox Consulting, effective as from September 15, 2021 (French language) (executed) |
70. Amendment 1 to Consulting Agreement (Avenant 1 au contrat de consultant) between OSE Immunotherapeutics and Protox Consulting, effective as from June 22, 2022 (executed) |
71. Consulting Agreement between OSE Immunotherapeutics SA and Protox Consulting, effective as from September 15, 2021 (translation from French) |
72. Amendment 1 to Consulting Agreement between OSE Immunotherapeutics SA and Protox Consulting, effective as from June 22, 2022 (translation from French) |
QPS |
73. Work Order No. 8 (CT01722) between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of October 18th, 2022 (executed) |
74. Work Order No. 9 (CT01723) between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of October 18th, 2022 (executed) |
75. Work Order No. 10 (CT01859) between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of June 12th, 2023 (executed) |
76. Master Bioanalytical Services Agreement between OSE Immunotherapeutics SA and QPS Holdings, LLC, effective as from July 1st, 2018 (executed) |
77. Amendment No.1 to Master Bioanalytical Services Agreement between OSE Immunotherapeutics SA and QPS Holdings, LLC, effective as from January 1st, 2019 (executed) |
78. Amendment No.2 to Master Bioanalytical Services Agreement between OSE Immunotherapeutics SA and QPS Holdings, LLC, effective as from July 1st, 2021 (executed) |
79. Change Order 1 to Work Order No, 8 (CT01722) between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of September 13, 2023 (executed) |
80. Work Order No. 11 between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of August 11th, 2023 (executed) |
81. Work Order No. 12 between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of August 11th, 2023 (executed) |
82. Work Order No. 13 between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of August 11th, 2023 (executed) |
83. Work Order No. 14 between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of August 11th, 2023 (executed) |
84. Work Order No. 15 between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of October 13th, 2023 (executed) |
85. Work Order No. 16 between OSE Immunotherapeutics SA and QPS Netherlands BV - OSE-230, effective as of December 6th, 2023 (executed) |
RETROGENIX |
86. Statement of Work (SOW) - OSE Immunotherapeutics SA - Antibody Comprehensive Study RP2482 (CRL-473691) - 31 October 2023 |
Schedule 10.2.14 OSE Publications |
List of Publications |
19 July 2023 Publication: ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression. Lavy M et al. Front Immunol. 2023 Jul 19;14:1196731. doi: 10.3389/fimmu.2023.1196731. eCollection 2023. |
20-23 JUNE 2023 FOCIS 2023 ANNUAL MEETING - 20-23 JUNE, BOSTON Date: June 20 Poster. Presenter: Vanessa Gauttier, Researcher, OSE Immunotherapeutics Tu 220 - "Agonist anti-ChemR23 mAb inhibits NETosis and neutrophil-mediated inflammation" |
28 April 2023 3rd RESOLUTION DAYS: Besançon, France . Oral presentation Vanessa Gauttier OSE Immunotherapeutics "Anti-ChemR23 agonist pro-Resolutive mAbs" |
16 November 2022 PEGS 2022 communication - Title: "Agonist Anti-ChemR23 Antibody for Inflammatory Diseases", oral presentation in the session "Biotherapeutics for GPCR Targets" on November 16th at 5:30pm by N. Poirier. |
1st June 2021 NAT 2021 ANNUAL MEETING NANTES : oral presentation, Presenter: Charlene Trilleaud, Engineer, OSE Immunotherapeutics "Agonist anti-ChemR23 mAb blunts tissue neutrophil accumulation and triggers chronic colitis inflammation resolution" |
10-15 April 2021 AACR Virtual Meeting April 10-15 2021 E-Poster Presentations . OSE-230, novel monoclonal antibody agonist therapy triggering resolution of chronic inflammation. |
2 April 2021 Publication: Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution. Trilleaud C et al. Sci Adv. 2021 Apr 2;7(14):eabd1453. doi: 10.1126/sciadv.abd1453. Print 2021 Apr. |
30 October 2020 FOCIS 2020 ANNUAL MEETING 30 October SAN FRANCISCO : virtual oral presentation, Presenter: Vanessa Gauttier, Researcher, OSE Immunotherapeutics "Agonist anti-ChemR23 mAb blunts tissue neutrophil accumulation and triggers chronic colitis inflammation resolution" |
12-14 Nov 2019 SFI: Poster:"Antibody-mediated ChemR23 resolutive activation prevents chronic inflammation in preclinical models of colitis" |
6 April 2018 1st RESOLUTION DAYS: oral presentation Presenter: Charlène Trilleaud, Triggering the resolution pathway with an agonistic anti ChemR23 mAb ameliorates recovery in colitis models |
Schedule 13.8.3 ADR Procedures |
Any Dispute referred to ADR under this Agreement shall be resolved as follows: |
1. To begin an ADR proceeding, a Party shall provide written notice to the other Party of the Dispute to be resolved by ADR in accordance with the provisions of this Schedule 13.8.3 and under the rules of the International Chamber of Commerce (the "ICC"), as modified by the procedures set forth in this Schedule 13.8.3 ... |
2. Within twenty-one (21) days following the initiation of the ADR proceeding, the Parties shall select a mutually acceptable independent, impartial, and conflicts-free neutral to preside in the resolution of all issues in this ADR proceeding. If the Parties are unable to agree on a mutually acceptable neutral within s... |
3. No earlier than twenty-eight (28) days or later than fifty-six (56) days after selection, the Neutral shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place at New York, New York. |
4. At least seven (7) days prior to the hearing, each Party shall submit the following to the other Party and the Neutral: |
(a) a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the Neutral; |
(b) a list of any witnesses such Party intends to call at the hearing and a short summary of the anticipated testimony of each witness; |
(c) a proposed ruling on each issue to be resolved, together with a request for a specific damage award or other remedy for each issue. The proposed ruling shall not contain any recitation of the facts or any legal arguments, and the proposed remedy shall not include any punitive damages. The proposed ruling and the pr... |
(d) a brief in support of such Party's proposed rulings and remedies; provided that the brief shall not exceed twenty (20) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. |
Except as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be required or permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents. |
5. The hearing shall be conducted on two (2) consecutive days and shall be governed by the following rules: |
(a) Each Party shall be entitled to five (5) hours of hearing time to present its case. The Neutral shall determine whether each Party has had the five (5) hours to which it is entitled. |
(b) Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents, or other evidence, to cross-examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examinatio... |
(c) The Party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address therein not only issues it raised but also any issues raised by the responding Party. The responding Party, if it chooses to make an opening statement, also shall address all issues raised in the ADR.... |
(d) Except when testifying, witnesses shall be excluded from the hearing until closing arguments. |
(e) Settlement negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. As to all other matters, the Neutral shall have sole discretion regarding the admissibility of any evidence. |
6. Within seven (7) days following completion of the hearing, each Party may submit to the other Party and the Neutral a post-hearing brief in support of its proposed rulings and remedies; provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation sh... |
7. The Neutral shall rule on each disputed issue within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one (1) of the Parties on each disputed issue but may adopt one (1) Party's proposed rulings and remedies on some issues and the other... |
8. The Neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: |
(a) If the Neutral rules in favor of one (1) Party on all disputed issues in the ADR, the losing Party shall pay one hundred percent (100%) of such fees and expenses. |
(b) If the Neutral rules in favor of one (1) Party on some issues and the other Party on other issues, the Neutral shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The Neutral shall allocate fees and expenses in a way that bears a reasonable r... |
9. The rulings of the Neutral and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction. |
10. Except as provided in paragraph 9 or as required by law, the existence of the Dispute, any settlement negotiations, the ADR proceeding, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed to be Confidential Information of both Parties. The Neutral shall hav... |
11. All ADR proceedings shall be conducted in the English language. |
12. Each Party shall have the right to be represented by counsel in all aspects of any ADR proceeding. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.